<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Pharma Policy on ELIZA on Steroids — Critical AI Analysis</title><link>https://elizaonsteroids.org/en/tags/pharma-policy/</link><description>Recent content in Pharma Policy on ELIZA on Steroids — Critical AI Analysis</description><generator>Hugo -- gohugo.io</generator><language>en-US</language><copyright>© 2026 ElizaOnSteroids</copyright><lastBuildDate>Thu, 18 Jun 2026 05:00:00 +0200</lastBuildDate><atom:link href="https://elizaonsteroids.org/en/tags/pharma-policy/index.xml" rel="self" type="application/rss+xml"/><item><title>The Kept and the Unkept Promise</title><link>https://elizaonsteroids.org/en/posts/kept-and-unkept-promise/</link><pubDate>Thu, 18 Jun 2026 05:00:00 +0200</pubDate><guid>https://elizaonsteroids.org/en/posts/kept-and-unkept-promise/</guid><description>mRNA technology received 15+ years of institutional advance credit for the promise of cancer — to this day no approved therapy standard. The peer-reviewed documented harm (myocarditis) got the maximum burden of proof. This is not a single-case debate. This is asymmetry as an institutional pattern.</description><media:content xmlns:media="http://search.yahoo.com/mrss/" url="https://elizaonsteroids.org/en/posts/kept-and-unkept-promise/featured.png"/></item></channel></rss>